Humacyte, Inc. (NASDAQ:HUMA) Short Interest Up 7.8% in October

Humacyte, Inc. (NASDAQ:HUMA) saw a large increase in short interest in the month of October. As of October 31st, there was short interest totalling 5,500,000 shares, an increase of 7.8% from the October 15th total of 5,100,000 shares. Approximately 7.4% of the company’s shares are sold short. Based on an average trading volume of 710,900 shares, the days-to-cover ratio is presently 7.7 days.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Piper Sandler reduced their price target on Humacyte from $3.50 to $3.00 and set a “neutral” rating for the company in a research report on Friday, November 10th. Benchmark reissued a “buy” rating and issued a $16.00 price target on shares of Humacyte in a research report on Tuesday, August 15th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $7.00 price target on shares of Humacyte in a research report on Thursday, September 21st.

Humacyte Stock Up 3.3 %

NASDAQ:HUMA traded up $0.08 during mid-day trading on Friday, hitting $2.52. 345,727 shares of the company’s stock traded hands, compared to its average volume of 454,380. The company has a fifty day moving average of $2.64 and a 200 day moving average of $3.22. Humacyte has a twelve month low of $1.96 and a twelve month high of $5.60. The company has a market capitalization of $260.64 million, a P/E ratio of -2.90 and a beta of 1.22. The company has a debt-to-equity ratio of 0.46, a quick ratio of 6.79 and a current ratio of 6.79.

Insider Activity at Humacyte

In other Humacyte news, CEO Laura E. Niklason sold 2,000,000 shares of the company’s stock in a transaction on Thursday, September 14th. The stock was sold at an average price of $2.78, for a total value of $5,560,000.00. Following the completion of the sale, the chief executive officer now directly owns 6,191,140 shares in the company, valued at approximately $17,211,369.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Humacyte news, CEO Laura E. Niklason sold 2,000,000 shares of the company’s stock in a transaction on Thursday, September 14th. The stock was sold at an average price of $2.78, for a total value of $5,560,000.00. Following the completion of the sale, the chief executive officer now directly owns 6,191,140 shares in the company, valued at approximately $17,211,369.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Laura E. Niklason sold 602,443 shares of the company’s stock in a transaction on Monday, August 21st. The stock was sold at an average price of $3.39, for a total value of $2,042,281.77. Following the completion of the sale, the chief executive officer now owns 8,191,140 shares of the company’s stock, valued at $27,767,964.60. The disclosure for this sale can be found here. 23.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. increased its holdings in shares of Humacyte by 13.2% in the second quarter. BlackRock Inc. now owns 4,304,505 shares of the company’s stock valued at $12,311,000 after purchasing an additional 501,265 shares during the period. Vanguard Group Inc. boosted its stake in shares of Humacyte by 107.3% in the first quarter. Vanguard Group Inc. now owns 2,422,020 shares of the company’s stock worth $17,099,000 after buying an additional 1,253,788 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Humacyte by 4.6% in the second quarter. Geode Capital Management LLC now owns 1,101,967 shares of the company’s stock worth $3,152,000 after buying an additional 48,034 shares during the last quarter. State Street Corp boosted its stake in shares of Humacyte by 57.3% in the second quarter. State Street Corp now owns 1,039,280 shares of the company’s stock worth $2,972,000 after buying an additional 378,485 shares during the last quarter. Finally, Northern Trust Corp boosted its stake in shares of Humacyte by 3.7% in the third quarter. Northern Trust Corp now owns 518,586 shares of the company’s stock worth $1,519,000 after buying an additional 18,578 shares during the last quarter. 27.36% of the stock is owned by institutional investors and hedge funds.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs).